0900 – 0915 hrs

Opening Remarks

0915 – 0935 hrs


ASEAN MedTech: Trend and Analysis

0935 – 1015 hrs


ASEAN Regulatory Policy Updates

1015 – 1055 hrs

Panel Discussion

Pathway into ASEAN-strategies and approaches

1055 – 1100 hrs

Closing Remarks

1230 – 1240 hrs

Opening Remarks

1240 – 1305 hrs


New Trends of Out-of-hospital Care and Demands for Innovative Medical Technologies in China

Fireside Chat

The Formulation of Out-of-hospital Care Models

1305 – 1330 hrs

Presentation followed by Q&A

DRG-based Market Access of the Innovative Medical Technologies

1330 – 1355 hrs

Presentation followed by Q&A

Regulatory Green Pathways into China

1355 – 1400 hrs

Closing Remarks

Please select a Menu From Setting!

Alicia Chang

Currently, Alicia manages cross-functional work of APACMed in China, including government affairs and market access, regulatory issues, digital health pathways, and China’s MedTech collaboration with the broader region.

Prior to joining APACMed, Alicia worked as the Chief Liaison Officer and senior international manager at CCCMHPIE for over 10 years, to drive bilateral and multilateral cooperation programs with a number of health-related government and non-government bodies in China.

She has extensive experience in driving projects under the governmental framework, public relations, policy analysis, advocacy programs, seminars, and events. She has been a key facilitator of multiple government-led bilateral and multilateral cooperation mechanisms, including the China-UK healthcare working group, China-CEEC Alliance for Public Health, China-ASEAN Healthcare Products Expo, etc. She was leading a number of global health projects, including WHO pre-qualification Studies on China’s MedTech industry.

An EU-certified conference interpreter, Alicia received her master’s degree in applied linguistics from the University of International Business and Economics. She has also completed her second master’s degree in Public Health from the Vanke School of Public Health at Tsinghua University.

John Eng

John Eng is VP of the Healthcare Division at the Singapore Economic Development Board (EDB). In his current role, he leads a team to engage with global companies and develop strategies to position Singapore as a hub for medical technology. Prior to this, he completed a secondment with the Food & Nutrition innovation strategy and initiatives at the Agency for Science Technology and Research and led the Agri-Food division at EDB. He was previously based in EDB’s Chicago Office from 2015-18 as Regional Director, Americas, facilitating investments in industries such as biomedical sciences, food & nutrition and professional services. John completed a MS in Bioengineering at the University of California, Berkeley and San Francisco and a BSc with Honours in Biological Sciences at Singapore’s Nanyang Technological University.

Frank Mei

Frank is a Certified Practicing Accountant of CPA Australia. He has over 24 years of risk consulting experience in China and Asia Pacific. He became Partner in Charge of Risk Consulting for KPMG China in 2019. Risk Consulting includes Forensic, Internal Audit and Risk Compliance, Financial Risk Management, Actuarial and IT Advisory.

Frank has worked primarily in areas of internal audit, corporate governance, internal controls and risk management and strategic risk advisory. His industry focus includes manufacturing, life science, energy and resources and technology. Frank has been working closely with Chinese regulators and was involved in the drafting of various risk and control regulations.

Salbiah Yaakop

Ms Salbiah Yaakop has more than 30 years of working experience, and is currently the Director of Policy and Strategic Planning Division of the Medical Device Authority, Ministry of Health Malaysia. Here, her main functions are managing the development of policies and regulatory documents, guidance documents and guidelines; managing international affairs and inter-agency agenda; industry affairs; managing events; provide trainings and consultancy and perform other specific projects. She also performed quality management system audits; medical device registration and licensing evaluations and verifications prior to her current role. She often represents MDA in other government and non-government meetings and programs and initiatives.She was the past Global Harmonization Working Party (GHWP) Technical Committee Chair, and currently GHWP Working Group 8 Chair on Standards for Medical Devices for the second term. She is also the Convenor for ISO/TC 210/WG 7 on Good Engineering Maintenance Management, and Chairperson of various Committees in MDA. She is also the Chairperson of two Technical Committees and a member of several National Standards Committees, Technical Committees and Working Groups related to medical devices in the national standards system. She is passionate about achieving global harmonization, and working towards securing bilateral cooperation and mutual recognitions with other countries in the areas of medical device standards and regulatory control.

Helsy Pahlemy

Helsy Pahlemy is a Pharmacist from University of Indonesia. She got a bachelor degree and Magister Program from University of Indonesia. She start career as government employee at Medical Devices Division. She loves to playing tennis dan having guitar lesson on her free time. Rigt Now, she is responsible on sertification on Medical Devices Distributor.

May Ng

May had her start in the In-Vitro Diagnostics (IVDs) industry since 1990s. Within a decade of work with the Health Sciences Authority (HSA) in Singapore, she played a key role in establishing the medical devices branch and also, the local and regional medical device guidance. Subsequently, she became the Regulatory Director at Biosensors International Group, a manufacturer of interventional cardiology drug-device products for a number of years before setting up ARQon. May also the Regulatory and Quality Director in Endofotonics, a start-up manufacturer for In vivo Molecular Diagnostic (IMDx). Her experience in the design and manufacturing sites as well as in the commercial industry and as the local regulator enables her to guide all relevant departments during the entire product life cycle on the regulatory strategy and documentation to meet the global registration requirements and compliance.

Dr. Koh Hau-Tek

Striving for excellent financial, organizational management & clinical outcomes, Dr Koh integrates business management and medical practice with a track record.
A bridge between clinical staff and top management/shareholders, he harnesses the strengths of each to enhance synergy with alignment and purpose; ultimately to create greater enterprise value in the healthcare industry.
He also believes in “People, purpose and passion” 3Ps – key elements for delivering consistently in healthcare management.

Yizhi Lin

With more than a decade of extensive international experience working in Asian and African countries, Yizhi Lin is a highly regarded expert in the field of Point-of-Care molecular diagnostic Testing. He serves as a council member for the 12th session of the Chinese Anti-Tuberculosis Association and is a founding committee member of the Genetic Testing Subsection of the Chinese Medical Equipment Association. Additionally, he has made significant contributions to medical and telecommunications sectors as an investor and industry expert.Lin and his team have been instrumental in driving innovation in POCT technology, resulting in numerous patent applications and significant contributions to global health initiatives, including the response to COVID-19 and tuberculosis.

Yeo Su Ling

In the Venture Creation and Growth Group under Innovation and Enterprise division, Su Ling is responsible for programmes, partnerships and creation of spin offs, in both science & engineering and biomedtech areas. Su Ling engages with VCs, serial entrepreneurs and corporates to co-create successful and sustainable spin offs leveraging on deep tech technologies developed at A*STAR. She will also support these spin offs in fund raising, business development, M&A activities and corporate partnerships.

Prior to A*STAR, she was at Temasek Life Sciences Laboratory (“TLL”), where she was managing business development and Intellectual Property including forming JVs with strategic partners.. Before TLL, she was at BioOne Capital, an EDB investment arm, focussing on investments in biotech and medtech companies globally. She has served on the Board of Directors, renumeration and audit committees of portfolio companies. She has also spent time in start-ups in the drug and vaccine development space.

Su Ling obtained her PhD in Neurobiology.

Dr. Abhishek Bhatia

Dr Abhishek is a physician, economist, and international affairs graduate with over five years of experience in clinical medicine, community health, academia and multilateral non-governmental organizations. He has worked with patients from socio-economically disadvantaged populations and supported diagnosis, treatment, and continuous care in the domains of maternal and child nutrition, paediatric cancer, chronic paediatric blood disorders, among others. His passion to solve global health challenges and specifically to improve access to healthcare in Low- and Middle-Income Countries has driven him in his academic and experiential pursuits. Currently, he is serving as the Director for The Voices Project, an independent multilateral healthcare research and policy shaping platform in Singapore. The platform convenes experts, patient advocates, pharmaceutical firms, government agencies, academic researchers, and non-governmental organizations to uncover insights into public health challenges and create a well-represented discourse with the aim of driving public health policy reform and improving the lives of people.

Jon Bastow

Jon Bastow helps organisations accelerate innovation across R&D and Access in healthcare. He helps health systems prepare to harness innovation, by optimising settings of care, and improved linkage across diagnostics, treatments, vaccines and other tools.He brings over 35 years of experience, having led projects across multiple diseases. He has held senior roles in pharmaceutical companies and international organisations such as FIND and The Global Fund, building partnerships between private sector healthcare and tech companies, NGO’s and governments addressing major problems of poverty. Jon is a member of the Chartered Institute of Marketing, holds degrees in Biochemistry and Philosophy and has given lectures at IMD, London Business School, INSEAD and the Graduate Institute in Geneva. He also serves on various boards in the healthcare space and beyond.

Dr. Ming Xu

Currently, Dr. Ming Xu is a Professor and the Dean of the Department of Global Health at School of Public Health of Peking University, as well as the Associate Dean of the Institute for Global Health and Development of Peking University. He has rich work experience in global health and the development of the healthcare industry. He was the Head of the Department for Emerging Economies and previously the Senior Political Advisor for External Relations at the Global Fund to Fight AIDS, Tuberculosis and Malaria in Switzerland. Prior to that, he was the Vice President of China Chamber of Commerce for the Import and Export of Medicines and Health Products under the Ministry of Commerce of China. Earlier, he served in the United Nations Iraq-Kuwait Observation Mission and the Chinese Embassy in the Republic of Korea. When working with the Global Fund, his focus was mainly on the prevention and control of major infectious diseases and health system strengthening in the implementing countries, and building up collaborations with emerging economies in the health field. When working in China, he participated a lot in formulating the policies and regulations of China’s healthcare industry, ranging from the promotion of trade and investment, regulation of medicinal products, to the enhancement of the international competitiveness of companies. He was the chair and PI of key health projects, and the head or member of evaluation groups to review major health projects at the national level. He currently serves as a member of the Technical Advisory Panel (TAP)of the Pandemic Fund and the World Health Organization’s Technical Advisory Group on Local Production and Technology Transfer of Health Products(TAG-LPTT) .

He got a Ph.D. in industrial economics from Fudan University and completed his post-doctoral fellowship at Guanghua School of Management of Peking University. He has written more than one hundred papers and articles in journals and specialized publications.

Prof. Lan Yao

Prof. Lan Yao, Dean of School of Medicine and Health Management, Tongji Medical College of Huazhong University of Science and Technology, Professor, Doctoral Supervisor, Ministry of Education New Century Excellent Talents, Executive Director of HUST Base of National Institute of Healthcare Security, Director of Primary Health Care Branch of China International Exchange and Promotive Association for Medical and Health Care, Vice Director of Health Insurance Branch of China Health Economics Association, Executive Director of China Health Insurance Research Association, Executive Director of Community Health Association of China, Vice President of Wuhan Medical Insurance Research Association, Vice President of Wuhan Community Health Association, Consulting expert of the Standing Committee of the 15th People’s Congress of Wuhan, Member of the Advisory Committee of Shenzhen Community Health Association. She has served as an advisor to the Health Bureau of the Macao Special Administrative Region. In addition, she was the chief editor of the second edition and third editions of textbook entitled “Medical Security”, with a total of eight books edited. As a project leader, she has presided over more than 80 scientific research projects of the National Natural Science Foundation of China, the National Health Commission, the Ministry of Human Resources and Social Security, the National Development and Reform Commission, the Ministry of Civil Affairs, the Ministry of Science and Technology, the World Health Organization Representative Office in China, the United Nations Children’s Fund, etc. More than 130 academic papers were published in various authoritative journals at home and abroad. She has received 8 awards, including the “China Medical Award” and the Third Prize of Hubei Provincial Scientific and Technological Progress. Main research areas: health economy, health policy, medical security, and primary health care.

Yi Feng Lai

Yi Feng currently serves in Singapore Ministry of Health Office for Healthcare Transformation (MOHT) as a senior project manager. He holds joint appointments as an associate staff (pharmacist) with the National University Health System, and adjunct lecturer with the National University of Singapore. Graduated from National University of Singapore (NUS) with BSc (Pharmacy) (Hons) in 2010, Yi Feng started practicing as a registered pharmacist at Singapore General Hospital, and was actively involved in a range of activities that encompassed clinical services, operational matters, education and research. In 2012, Yi Feng joined the Sengkang Health team planning for a new regional health system for Northeastern Singapore. In 2014, he was awarded Sengkang Health Scholarship to pursue Master in Public Health (MPH) at Saw Swee Hock School of Public Health, NUS, and subsequently a half-scholarship from International Society for Quality in Health Care’s Fellowship Program for its fellowship (FISQua). Graduated with MPH and FISQua in 2015, Yi Feng continued his service with Sengkang General Hospital (SKH) as a Senior Pharmacist who oversaw the implementation of Outpatient Pharmacy Automation and pharmacy department’s research efforts. A believer of continuous research and improvement, Yi Feng was extensively involved in health services research spanning clinical safety, quality and care integration, and had authored 15 peer-reviewed publications to date. He is also currently an appointed peer reviewer with both Journal of American College of Clinical Pharmacy (JACCP) and International Journal for Quality in Health Care (IJQHC). Externally, Yi Feng is a grassroots leader with Bedok Community Centre and People’s Association.

Grace Wang

Grace Wang is a Partner based in L.E.K.’s Shanghai office. She has over 10 years of experience in strategy consulting, with a focus on the life science and healthcare practice.

Grace has extensive experience supporting international and Chinese clients in medical device, pharmaceutical, life science tools and broader healthcare sectors on a wide range of engagements including growth strategy, pricing and market access, China localization and transaction support​.

Grace graduated from Fudan University with a Double Master’s Degree in International Management from Fudan and Bocconi University​.

Dr. Pei Li

Dr. Pei Li is a Researcher of HUST Sub-Base of National Institute of Healthcare Security. Dr. Pei Li graduated from Peking Union Medical College and served as chief physician in the First Affiliated Hospital of Tsinghua University and the People’s Liberation Army General Hospital (301 Hospital). He also has extensive experience working in non-public hospitals and has been a core member of the Hospital Management Center of China Resources Medical since 2015.

Yvonne Lee

Yvonne holds a PhD in Medicine from University of New South Wales and Master of Public Health from Mount Sinai School of Medicine, New York. Her core competencies are real- world clinical evidence generation, health economics, health technology assessments and market access. Yvonne has more than 18 years of working experience across different organizations including academia, government, pharmaceutical and medtech industry. She has established track record publications and worked in the following therapeutic areas: oncology, infectious disease, diabetes, cardiovascular and stroke. She received further training in cancer epidemiology at International Agency for Research on Cancer (IARC), patient centered care at US Patient-Centered Outcome Research Institute (PCORI) and alumni of Eureka 3rd International Certificate Program in Translational Medicine (2010). Yvonne drives multi-stakeholder collaborations to improve patient access to innovative medical technologies across Asia Pacific and she advocates for patient-centered care.

Yawen Wang

Yawen Wang, M.D., Reviewer, Division of Clinical and Biostatistics I, Center for Medical Device Evaluation (CMDE) of NMPA. She is also a member of Clinical Evaluation Working Group (MDCE) of IMDRF, and participated in the harmonization of Documents of Clinical Evaluation.

Ruslan Tulenov

Ruslan Tulenov from Kazakhstan, has been living and working in China for 15 years. He is actively engaged in public welfare activities, and has been praised by Chinese President Xi Jinping for donating rare RH-negative blood, also known as “panda blood,” to Chinese patients.

In October 2019, Ruslan Tulenov joined the Hainan International Economic Development Bureau (Hainan IEDB) as the global press officer and deputy director for investment promotion. He has been engaged in promotion of Hainan Free Trade Port, developing relations with foreign investment agencies and broadening global network for Hainan IEDB, trying to help global investors better locate potential projects and partners in the free trade port, and organizing the China International Consumer Products Expo (a.k.a Hainan Expo), the only national-level expo that targets consumer goods.

Studied at Hainan Universtiy and Beijing University of Science and Technology, he holds a bachelor’s degree in Economics.

Jason Guo

Mr. Jason (Jian) Guo earned double-bachelor’s degrees from STU, China and acquired master degree of International Business Administration from UBC (University of British Columbia), Canada. He is now working for Abbott Global Regulatory Service Dept. as regional RA director for APAC to oversee strategic regulatory planning and ensure regulatory compliance of Abbott medical device business in this region. Prior to join Abbott, Mr. Jason Guo had worked for multiple reputable US and European medical device MNCs, where he accumulated rich experiences in areas of QMS/GMP, post-market surveillance, regulatory approvals, intelligence, compliance, and policy shaping. Mr. Jason Guo is also serving APACMed RA Committee as vice chairperson to actively advocate regulatory harmonization, convergency, reliance and capacity building activities.